Table 1 Evaluation and visit schedule .... | American Society of Hematology

Table 1

Evaluation and visit schedule

	Visit 1 (month 0)	Visit 2 (month 3)
Patient characteristics
Sociodemographic data	X
Medical history and current comorbidity	X
Disease-related information
Disease history	X
Current clinical status	X	X
Concomitant medications
Medications: risk for Rx-Rx interactions	X	X
Physician variables
Sociodemographic data	X
Education	X
Specialty	X
Practice environment	X
Number of active patients with CML	X
Time spent with patients: newly diagnosed (first consultation)	X
Time spent with patients: during treatment	X
Use of scientific information / evidence-based practice	X
Use of patient awareness and support materials	X
Perspectives on patient compliance	X
Patient compliance
Basel Assessment of Adherence Scale, Visual Analog Scale, 30 days retrospective, patient interview	X	X
Basel Assessment of Adherence Scale, Visual Analog Scale, 30 days retrospective, family member interview	X	X
Pill count (delta grams taken vs grams prescribed), 90 days retrospective		X
Appointment noncompliance, 30 days retrospective	X	X
Physician Visual Analog Scale rating of patient compliance, 30 days retrospective	X	X
Patient variables
Long-Term Medication Behavior Self-Efficacy Scale (adapted for CML/imatinib)	X
Patient Assessment of Chronic Illness Care (PACIC), 30 days retrospective	X	X
Symptom experience and distress, 30 days retrospective	X	X
Understanding of disease and treatment	X	X
Functional status / quality of life (SF-8), 30 days retrospective	X	X
Patient knowledge-seeking behavior, 90 days retrospective		X
Response parameters
CML: hematologic response, cytogenetic response, molecular response	X	X
Treatment-related
Number of visits to GP between visit 1 and visit 2 related to CML/imatinib		X
Number of visits to specialist between visit 1 and visit 2 related to CML/imatinib		X

	Visit 1 (month 0)	Visit 2 (month 3)
Patient characteristics
Sociodemographic data	X
Medical history and current comorbidity	X
Disease-related information
Disease history	X
Current clinical status	X	X
Concomitant medications
Medications: risk for Rx-Rx interactions	X	X
Physician variables
Sociodemographic data	X
Education	X
Specialty	X
Practice environment	X
Number of active patients with CML	X
Time spent with patients: newly diagnosed (first consultation)	X
Time spent with patients: during treatment	X
Use of scientific information / evidence-based practice	X
Use of patient awareness and support materials	X
Perspectives on patient compliance	X
Patient compliance
Basel Assessment of Adherence Scale, Visual Analog Scale, 30 days retrospective, patient interview	X	X
Basel Assessment of Adherence Scale, Visual Analog Scale, 30 days retrospective, family member interview	X	X
Pill count (delta grams taken vs grams prescribed), 90 days retrospective		X
Appointment noncompliance, 30 days retrospective	X	X
Physician Visual Analog Scale rating of patient compliance, 30 days retrospective	X	X
Patient variables
Long-Term Medication Behavior Self-Efficacy Scale (adapted for CML/imatinib)	X
Patient Assessment of Chronic Illness Care (PACIC), 30 days retrospective	X	X
Symptom experience and distress, 30 days retrospective	X	X
Understanding of disease and treatment	X	X
Functional status / quality of life (SF-8), 30 days retrospective	X	X
Patient knowledge-seeking behavior, 90 days retrospective		X
Response parameters
CML: hematologic response, cytogenetic response, molecular response	X	X
Treatment-related
Number of visits to GP between visit 1 and visit 2 related to CML/imatinib		X
Number of visits to specialist between visit 1 and visit 2 related to CML/imatinib		X

View Large

This Feature Is Available To Subscribers Only